Business

New data from HouseCanary reveals COVID-19’s resurgence is creating an attractive ‘seller’s market’ for homeowners

Despite Resurgent Homebuyer Demand, New Listing Volume Dropped 12% on a Week-Over-Week Basis and Net New Listings are Down 17.5% Compared to the Same Point in 2019 Sustained Supply Constraints Throughout the Spring and Summer Have Kept Listing Prices Above Pre-Pandemic Levels

Business

Dun & Bradstreet reports second quarter 2020 financial results

SHORT HILLS, N.J.–(BUSINESS WIRE)–Dun & Bradstreet Holdings, Inc. (NYSE: DNB), a leading global provider of business decisioning data and analytics, today announced unaudited financial results for the second quarter ended June 30, 2020. A reconciliation of U.S. generally accepted accounting principles (“GAAP”)

Business

Zoetis announces second quarter 2020 results

Reports Flat Revenue of $1.5 Billion, and Net Income of $377 Million, or $0.79 per Diluted Share, Increasing 2% and 3%, Respectively, on a Reported Basis for Second Quarter 2020 Reports Adjusted Net Income of $427 Million, or Adjusted Diluted EPS of

Business

Merck Animal Health completes acquisition of IdentiGEN

Strategic Transaction Enhances Farm-to-Table Animal Traceability Solutions for Livestock and Aquaculture MADISON, N.J.–(BUSINESS WIRE)–$MRK #AnimalHealth–Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the

Business, Health Care

Merck and Hanmi Pharmaceutical enter into licensing agreement to develop Efinopegdutide, an investigational once-weekly therapy for nonalcoholic steatohepatitis (NASH)

KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Hanmi Pharmaceutical today announced that the companies have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A), Hanmi’s investigational